Epileptic seizures as the sole manifestation of neuro-Behçet's disease: Complete control under interferon-alpha treatment

Seizure

Volumn 17, Issue 8, 2008, Pages 744-747

  Chroni, Elisabeth ^a   Monastirli, Alexandra ^a   Polychronopoulos, Panayiotis ^a   Pasmatzi, Efi ^a   Georgiou, Sophia ^a   Vryzaki, Eleftheria ^a   Tsambaos, Dionysios ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Beh et's disease; Epilepsy; Interferon alpha; Seizures

Indexed keywords

ETIRACETAM; LAMOTRIGINE; OXCARBAZEPINE; RECOMBINANT ALPHA2A INTERFERON; TOPIRAMATE; VALPROIC ACID;

ADULT; ARTICLE; BEHCET DISEASE; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; DRUG SAFETY; ELECTROENCEPHALOGRAPHY; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RELAPSE; REMISSION; SEIZURE;

BEHCET SYNDROME; EPILEPSY; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON ALFA-2A; MALE; MIDDLE AGED;

EID: 55549135676     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2008.05.008     Document Type: Article

References (17)

1. Haghighi A.B., Pourmand R., and Nikseresht A.-R. Neuro-Behçet disease: a review. Neurologist 11 (2005) 80-89
2. International Study Group for Behçet Disease. Criteria for the diagnosis of Behçet' disease. Lancet 335 (1990) 1078-1080
3. Al-Mutawa S.A., and Hegab S.M. Behçet's disease. Clin Exp Med 4 (2004) 103-131
4. Joseph F.G., and Scolding N.J. Neuro-Behçet's disease in Caucasians: a study of 22 patients. Eur J Neurol 14 (2007) 174-180
5. Aykutlu E., Baykan B., Serdaroǧlu P., Gökyiǧit A., and Akman-Demir G. Epileptic seizures in Behçet disease. Epilepsia 43 (2002) 832-835
6. Mead S., Kidd D., Good C., and Plant G. Behçet's syndrome may present with partial seizures. J Neurol Neurosurg Psychiatry 68 (2000) 388-399
7. Aktekin B., Doǧan E.A., Oǧuz Y., and Karaali K. Epilepsia partialis continua in a patient with Behçet's disease. Clin Neurol Neurosurg 108 (2006) 392-395
8. Huang W.S., Chiu P.Y., Kao A., Tsai C.H., and Lee C.C. Decreased cerebral blood flow in neuro-Behçet's syndrome patients with neuropsychiatric manifestations and normal magnetic resonance imaging: a preliminary report. J Neuroimaging 12 (2002) 355-359
9. Tsambaos D., Eichelberg D., and Goos M. Behçet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 278 (1986) 335-336
10. Georgiou S., Monastirli A., Pasmatzi E., Gartaganis S., Goerz G., and Tsambaos D. Efficacy and safety of systemic recombinant interferon-alpha in Behçet's disease. J Int Med 243 (1998) 367-372
11. Kötter I., Günaydin I., Zierhut M., and Stübiger N. The use of interferon α in Behçet disease: review of the literature. Semin Arthritis Rheum 33 (2004) 320-335
12. Nichols J.C., Ince A., Akduman L., and Mann E.S. Interferon-alpha 2a treatment of neuro-Behçet disease. J Neuroophthalmol 21 (2001) 109-111
13. TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Efficacy and tolerability of the new antiepileptic drugs II. Treatment of refractory epilepsy. Neurology 62 (2004) 1261-1273
14. Nicolas J.M., Collart P., Gerin B., Mather G., Trager W., Levy R., et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos 27 (1999) 250-254
15. Levy R.H., and Collins C. Risk and predictability of drug interactions in the elderly. Int Rev Neurobiol 81 (2007) 235-251
16. Islam M., Frye R.F., Richards T.J., Sbeitan I., Donnelly S.S., Glue P., et al. Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res 8 (2002) 2480-2487
17. Nallani S.C., Glauser T.A., Hariparsad N., Setchell K., Buckley D.J., Buckley A.R., et al. Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia 44 (2003) 1521-1528